PAR 2.38% 20.5¢ paradigm biopharmaceuticals limited..

Application, page-5

  1. 4,420 Posts.
    lightbulb Created with Sketch. 6962
    A great read, thanks Gan_Gans...here is just one extract:

    "The present invention is based on the surprising finding that treatment with PPS showed a decrease in BMEL volume and, in some cases, complete reduction in BMELs in a patient with no post-treatment adverse events reported on follow-up. Therefore, PPS may be an improved alternative pharmaceutical option to NSAIDs and corticosteroids with potential disease modifying activity."

    " The finding implicates the potential effectiveness of PPS as a treatment option for BMELs and joint effusion in patients and for MCs in patients"

    In some cases a complete reduction in BMEL's was a pretty stunning read! I know PAR have stated that we reduce BMEL's...but totally eradicating them? I guess there is an extra chance of this if caught early etc.
    Note: MC's means Modic changes. Modic changes means pathological changes to the structure of the spine due to degradation of the spine. 1

    The stuff in that publication in regards to potential action on the spine is also quite extraordinary.

    This was the clinical results achieved in that report: (I haven't seen this detail before)

    Table 1. Clinical outcomes


    Figure imgf000030_0001


    Table 1 Legend

    Numerical Rating Scale (NRS) [33] is an 11-point scale (0-10). A state of no pain is 0 and the worst pain imaginable is 10.

    Lysholm Knee Score [34] is a total score of 0-100 is calculated based on the results from the eight functional components of the Lysholm knee score scale: Limp (5 points), Support (5 points), Locking (15 points), Instability (25 points), Pain (25 points), Swelling (10 points), Stair climbing (10 points), and Squatting (5 points). The total score is assigned to rating categories as follows: 95-100 indicates excellent, 84-94 indicates good, 65-83 indicates fair and <65 indicates poor function.


    ---------------------------------------------------------------------------------------

    And at what cost? Well as we know already but always good to see and hear it again:

    "In conclusion, no adverse events were reported with the use of PPS under the TGA SAS(B) in patients with Bone Marrow Edema Lesions and suffering from osteoarthritis."


    References
    1) https://www.raynersmale.com/blog/2015/8/21/modic-changes
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
20.5¢
Change
-0.005(2.38%)
Mkt cap ! $71.73M
Open High Low Value Volume
20.0¢ 21.0¢ 20.0¢ $152.8K 744.7K

Buyers (Bids)

No. Vol. Price($)
3 78174 20.5¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 84426 5
View Market Depth
Last trade - 16.10pm 01/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.